Market closed
Paragon 28/$FNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Paragon 28
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of revenue from the United States.
Ticker
$FNA
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
525
Website
Paragon 28 Metrics
BasicAdvanced
$1.1B
-
-$0.66
1.54
-
Price and volume
Market cap
$1.1B
Beta
1.54
52-week high
$13.13
52-week low
$4.65
Average daily volume
2M
Financial strength
Current ratio
3.508
Quick ratio
1.554
Long term debt to equity
85.263
Total debt to equity
86.216
Interest coverage (TTM)
-3.54%
Management effectiveness
Return on assets (TTM)
-8.18%
Return on equity (TTM)
-36.39%
Valuation
Price to revenue (TTM)
4.234
Price to book
8.36
Price to tangible book (TTM)
12.88
Price to free cash flow (TTM)
-24.598
Growth
Revenue change (TTM)
18.39%
Earnings per share change (TTM)
-5.83%
3-year revenue growth (CAGR)
20.21%
3-year earnings per share growth (CAGR)
36.41%
What the Analysts think about Paragon 28
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Paragon 28 stock.
Paragon 28 Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Paragon 28 Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Paragon 28 News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Stockholders to Learn More About the Investigation
Accesswire·1 day ago
Shareholder Alert: The Ademi Firm Investigates Whether Paragon 28, Inc. is Obtaining a Fair Price for its Public Shareholders
Business Wire·3 days ago
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act
Business Wire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Paragon 28 stock?
Paragon 28 (FNA) has a market cap of $1.1B as of March 15, 2025.
What is the P/E ratio for Paragon 28 stock?
The price to earnings (P/E) ratio for Paragon 28 (FNA) stock is 0 as of March 15, 2025.
Does Paragon 28 stock pay dividends?
No, Paragon 28 (FNA) stock does not pay dividends to its shareholders as of March 15, 2025.
When is the next Paragon 28 dividend payment date?
Paragon 28 (FNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Paragon 28?
Paragon 28 (FNA) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.